- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Theralase Technologies Inc. (TLT)
Theralase Technologies Inc. stock price live, this page displays TSXV TLT stock exchange data. View the TLT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Theralase Technologies Inc. real time stock price chart below.
What Is the Theralase Technologies Inc. Stock Price Today?
The Theralase Technologies Inc. stock price today is 0.175.
What Is the Stock Symbol for Theralase Technologies Inc.?
The stock symbol for Theralase Technologies Inc. is "TLT."
What Stock Exchange Does Theralase Technologies Inc. Trade On?
Theralase Technologies Inc. is listed and trades on the TSXV stock exchange.
Is Theralase Technologies Inc. a Good Stock to Buy?
Determining whether Theralase Technologies Inc.—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TLT quote. (ISIN: CA88337V1004)
What Is the Theralase Technologies Inc. Stock Price Today?
The Theralase Technologies Inc. stock price today is 0.175.
What Is the Stock Symbol for Theralase Technologies Inc.?
The stock symbol for Theralase Technologies Inc. is "TLT."
What Stock Exchange Does Theralase Technologies Inc. Trade On?
Theralase Technologies Inc. is listed and trades on the TSXV stock exchange.
Is Theralase Technologies Inc. a Good Stock to Buy?
Determining whether Theralase Technologies Inc.—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TLT quote. (ISIN: CA88337V1004)
0.175
-0.005(-2.78%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.175
0.180
52 wk Range
0.145
0.410
TLT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.1750.180
52 wk Range
0.1450.410
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
TLT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
0.700
Upside
+300.00%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 0.700
(+300.00% Upside)
Theralase Technologies Inc. Earnings Call Summary for Q1/2026
- Theralase reported Q1 2026 EPS of CAD -0.004, beating forecast of CAD -0.0422 by 90.52%; revenue rose 45% YoY to CAD 133,000
- Company completed Phase II bladder cancer study enrollment; plans New Drug Application submission in Q3 2026 with regulatory decision expected H1 2027
- Net loss improved 30% YoY to CAD 1,032,000 through significant R&D and administrative cost reductions; gross margin surged 392% to CAD 64,000
- Stock rose 2.22% after-hours to CAD 0.23; company preparing for U.S. IPO and plans to expand marketing initiatives as balance sheet strengthens
- Management emphasizes operational efficiency and strategic capital allocation; savings from reduced expenses to be reinvested in new clinical programs
Last Updated: 2026-06-09, 12:20 p/m
Read Full TranscriptEarnings
Latest Release
Aug 31, 2026
EPS / Forecast
-0.00 / -0.00
Revenue / Forecast
164K / 180K
Compare TLT to Peers and Sector
Metrics to compare | TLT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTLTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −14.7x | −5.5x | −0.4x | |
PEG Ratio | −0.85 | −0.03 | 0.00 | |
Price/Book | 8.2x | 2.0x | 2.6x | |
Price / LTM Sales | 69.6x | 12.2x | 3.0x | |
Upside (Analyst Target) | 288.9% | 195.3% | 56.4% | |
Fair Value Upside | Unlock | 16.5% | 7.9% | Unlock |
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and muscle invasive bladder cancer; and Ruvidar, a topical treatment for herpes simplex virus-1 lesions and an extracorporeal treatment for lymphoma, leukemia, and multiple myeloma. The company also researches, develops, manufactures, and distributes Cool Laser Therapy systems to healthcare practitioners for the healing of pain. Theralase Technologies Inc. is based in Toronto, Canada.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Theralase Technologies (TLT) Stock Price Today?
The Theralase Technologies stock price today is 0.175 CAD.
What Stock Exchange Does Theralase Technologies Trade On?
Theralase Technologies is listed and trades on the TSX Venture Exchange.
What Is the Stock Symbol for Theralase Technologies?
The stock symbol for Theralase Technologies is "TLT."
What Is the Theralase Technologies Market Cap?
As of today, Theralase Technologies market cap is 54.330M CAD.
What Is Theralase Technologies's Earnings Per Share (TTM)?
The Theralase Technologies EPS (TTM) is -0.014.
When Is the Next Theralase Technologies Earnings Date?
Theralase Technologies will release its next earnings report on Dec 02, 2026.
From a Technical Analysis Perspective, Is TLT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Theralase Technologies Stock Split?
Theralase Technologies has split 0 times.
How Many Employees Does Theralase Technologies Have?
Theralase Technologies has 20 employees.
What is the current trading status of Theralase Technologies (TLT)?
As of Oct 02, 2026, Theralase Technologies (TLT) is trading at a price of 0.175 CAD, with a previous close of 0.180 CAD. The stock has fluctuated within a day range of 0.175 CAD to 0.180 CAD, while its 52-week range spans from 0.145 CAD to 0.410 CAD.
What Is Theralase Technologies (TLT) Price Target According to Analysts?
The average 12-month price target for Theralase Technologies is 0.700 CAD, with a high estimate of 0.7 CAD and a low estimate of 0.7 CAD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +300.00% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.